Hong Kong Stock Announcement Nuggets | Huazhong Automotive: Establishing a partnership to focus on investing in emerging productivity, new energy, new materials, consumer goods and healthcare

Important matters:

China Biopharmaceutical (01177): TQH3906 “TYK2/JAK1 JH2 allosteric inhibitor” patch psoriasis phase II clinical trial has made positive progress

Huazhong Automotive (06830): Establishing a partnership to focus on investing in emerging productivity, new energy, new materials, consumer goods and healthcare

Cinda Biotech (01801): Daboxin® (ipimumab N01 injection) was approved by the State Drug Administration in conjunction with cindilizumab for new adjuvant treatment of colon cancer

Aberdeen Robotics (00370): Aberdeen Robotics and Tonghong Guard sign a product delivery agreement for a self-contained intelligent security robot

Hehuang Pharmaceutical (00013) announced that the marketing application for vanreglatinib (HMPL-453) for second-line treatment of intrahepatic cholangiocarcinoma in China has been accepted and included in priority review

The world's first adrenaline nasal spray to treat severe allergic reactions introduced by Yuanda Pharmaceutical (00512) was issued a drug registration certificate

Yimei International Holdings (01870): “Shaoguan Lechang 218 MW/436 MWH Electrochemical Independent Energy Storage Project” was officially approved for access to the Guangdong Power Grid

China's Hanwang (03788): High-grade COPPERHEAD underground gold mine receives approval for drainage project

Jiufulai (08611) subsidiary has established cooperative business with over 4,000 merchants covering more than 29 provincial regions in the Mainland

Operating performance:

Yichen Group (08365) announced annual results. Loss attributable to shareholders of HK$476.26 million narrowed 38.22% year-on-year

Baoji Capital (08168) announced annual results. Losses attributable to shareholders of HK$6.481 million decreased by 26.83% year-on-year

Xingqian Development (00640) announced annual results. Profit attributable to shareholders of HK$122 million increased 21.7% year over year